Dr. Garon on Immunotherapy for Patients With NSCLC

Edward B. Garon, MD
Published: Thursday, Aug 04, 2016


Edward B Garon, MD, director, Thoracic Oncology, Jonnson Comprehensive Cancer Center, UCLA, discusses the evolution of immunotherapy for the treatment of patients with non–small cell lung cancer (NSCLC).

The addition of immunotherapy agents to the treatment landscape of NSCLC has led to a very exciting time for a disease originally not believed to be immunogenic, Garon explains.

Today, evidence suggests that such agents could become the frontline choice for select patients with stage IV disease versus standard chemotherapy. 

<<< View more from the 2016 International Lung Cancer Congress


Edward B Garon, MD, director, Thoracic Oncology, Jonnson Comprehensive Cancer Center, UCLA, discusses the evolution of immunotherapy for the treatment of patients with non–small cell lung cancer (NSCLC).

The addition of immunotherapy agents to the treatment landscape of NSCLC has led to a very exciting time for a disease originally not believed to be immunogenic, Garon explains.

Today, evidence suggests that such agents could become the frontline choice for select patients with stage IV disease versus standard chemotherapy. 

<<< View more from the 2016 International Lung Cancer Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x